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Abstract
Drug induced liver injury (DILI) is a growing problem. Diagnostic methods to differentiate DILI 
caused by an adaptive immune response from liver injury of other causes or to identify the 
responsible drug in patients receiving multiple drugs, herbals, and/or dietary supplements 
(polypharmacy) have not yet been established. The lymphocyte transformation test (LTT) has been 
proposed as a diagnostic method to determine if a subject with an apparent hypersensitivity 
reaction has become sensitized to a specific drug. In this test, peripheral blood mononuclear cells 
(PBMC) collected from a subject are incubated with drug(s) suspected of causing the reaction. 
Cell proliferation, measured by the incorporation of [3H]-thymidine into new DNA, is considered 
evidence of a drug-specific immune response. The objectives of the current studies were to: 1) 
develop and optimize a modified version of the LTT (mLTT) and 2) investigate the feasibility of 
using the mLTT for diagnosing DILI associated with an adaptive immune response and identifying 
the responsible drug. PBMC collected from donors with a history of drug hypersensitivity 
reactions to specific drugs (manifested as skin rash) were used as positive controls for assay 
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optimization. Following optimization, samples collected from 24 subjects enrolled in the U.S. 
Drug-Induced Liver Injury Network (DILIN) were tested in the mLTT. Using cytokine and 
granzyme B production as the primary endpoints to demonstrate lymphocyte sensitization to a 
specific drug, most samples from the DILIN subjects failed to respond. However, robust positive 
mLTT responses were observed for two of four samples from three DILIN subjects with hepatitis 
due to isoniazid (INH). We conclude that the mLTT, as performed here on frozen and thawed 
PBMC, is not a reliable test for diagnosing DILI caused by all drugs, but that it may be useful for 
confirming the role of the adaptive immune response in DILI ascribed to INH.
Keywords
Allergic reactions; immuno-allergic; drug induced liver injury; drugs; hepatitis; lymphocytes; 
lymphocyte transformation test
Introduction
Drug induced liver injury (DILI) is a growing problem that is under-recognized and under-
reported (Bonkovsky et al. 2012; Chalasani et al. 2008, 2014, 2015). Among reasons for this 
are the growing numbers of drugs, herbals and dietary supplements that are consumed by 
billions of persons worldwide and the difficulties encountered in establishing a diagnosis of 
DILI (Agarwal et al. 2014). Even when the diagnosis is made, based upon a compatible 
history and time sequence of drug intake and development of liver injury, and exclusion of 
alternative causes, such as viral hepatitis, alcoholic liver injury, idiopathic auto-immune 
hepatitis, etc., it may be difficult to determine which of several possible candidate drugs or 
supplements is the cause of liver injury in the specific individual case. In order to gain better 
insights into DILI, the National Institutes of Health (NIDDK) established the US Drug 
Induced Liver Injury Network (DILIN) in 2004 and has funded work of this cooperative 
network since that time. The major goals of the Network have been to establish a registry 
and database and sample repository of patients with well-characterized idiosyncratic DILI 
(Fontana et al. 2009), in whom other possible causes have been reasonably excluded by a 
formal process of causality assessment (Rochon et al. 2008; Rockey et al. 2010). Among the 
major findings of this Network has been the realization that most idiosyncratic, non-dose 
related and unpredictable DILI is due to host immune responses to the causative drugs, 
herbals, or dietary supplements. Another has been that herbals and dietary supplements are 
becoming more frequent as causes (Navarro et al. 2014; Seeff et al. 2015).
Work from the Network recently showed that T cells are frequent in liver biopsies from 
patients with DILI (Foureau et al. 2015), and that risks of DILI development are associated 
with certain HLA types (Lucena et al. 2011; reviewed in Bonkovsky et al. 2012). Therefore, 
some cases of idiosyncratic DILI may be mediated by hypersensitivity or allergic reactions 
to the drug. These types of reactions, often referred to as immuno-allergic or allergic 
hepatitis, or immuno-allergic DILI, often (but not always) present with features that include 
laboratory findings of hepatocellular and/or cholestatic injury along with skin rash, facial 
edema, eosinophilia, fever, and/or lymphadenopathy (Fontana et al. 2010; Bonkovsky et al. 
2012). The mechanism for immuno-allergic DILI reactions has been hypothesized to be 
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mediated by drug- or drug metabolite-specific T-cells (referenced here simply as drug-
specific T-cells) (Ju 2005; Tujios and Fontana 2011; Kim et al. 2015). Activation of these 
drug-specific T-cells may lead to the generation of cytokine-producing and/or cytotoxic T-
cells that lead to liver injury. Indeed, liver biopsies from subjects with acute DILI with 
immuno-allergic features generally show abundant lympho-plasmacytic inflammation 
(Kleiner et al. 2014) with a predominantly CD8+ T-cell portal infiltrate (Foureau et al. 2015). 
Clinical cases with some of the symptoms similar to immuno-allergic DILI have been 
reported but it is not known if these reactions are true allergic reactions to the drug 
(mediated by drug-specific T-cells) or mediated by other mechanisms.
When drug-induced skin rashes are observed, the lymphocyte transformation test (LTT) has 
been used to provide evidence that the reactions were mediated by an allergic mechanism 
(Pichler and Tilch 2004; Kano et al. 2007; Lochmatter et al. 2009a b; Zawodniak et al 2010; 
Naisbitt et al. 2014). The LTT is an ex vivo assay in which peripheral blood mononuclear 
cells (PBMC) from the patient with a skin rash attributed to a drug are incubated with the 
suspected drug and lymphocyte proliferation is measured. Modifications of the LTT that 
involve measuring granzyme B and cytokine production as alternatives to [3H]-thymidine 
incorporation have also been developed for severe skin reactions (Stevens Johnson 
Syndrome, toxic epidermal necrolysis) (Porebski et al. 2013). Positive LTT responses have 
been reported in DILI cases using methods similar to that used for drug-induced allergic skin 
reactions. Several studies have evaluated the percentage of cases of drug-associated hepatitis 
that have positive LTT responses (Table 1) (Mizoguchi et al. 1975; Warrington et al. 1978; 
Yoshimura et al. 1994; Maria and Victorino 1997; Murata et al. 2003). In these studies, the 
percentage of positive LTT responses ranged from 12–56% for various drugs, to as high as 
95% for DILI ascribed to isoniazid (INH). It should be noted that the length of time between 
blood collection and processing the samples to PBMC were not always indicated in these 
reports. In general, it must be assumed that fresh PBMC were used for the assays, because 
the freezing of PBMC prior to use in the LTT was not described in these studies.
In the work reported here, the feasibility of using a modified LTT (mLTT), with cytokines 
and granzyme B production as the primary endpoints to demonstrate lymphocyte 
sensitization to a specific drug, was investigated in a collaborative study with the Drug 
Induced Liver Injury Network (DILIN) (Fontana et al. 2009; Rockey et al. 2010; Kleiner et 
al. 2014; Chalasani et al. 2015) to determine the utility of the LTT for diagnosing DILI 
associated with an adaptive immune response. These studies involved the use of PBMC 
samples collected from DILI subjects by DILIN investigators. As part of the Prospective 
Protocol of DILIN, blood samples were already being collected and sent to a central 
repository for PBMC isolation and freezing. For this ancillary study, additional blood 
samples were also collected and PBMCs were prepared for evaluation in the mLTT.
The first objective of this study was to evaluate the performance of the mLTT using PBMC 
samples from healthy human donors with and without known drug allergies (manifested as 
skin reactions). The second objective was to evaluate responses of PBMC samples obtained 
from DILIN subjects in the mLTT. Cytokine and granzyme B production were evaluated to 
determine whether the mLTT could aid in the diagnosis of DILI reactions associated with an 
adaptive immune response and identify the responsible drug.
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Materials and Methods
The US DILIN has been described previously (Chalasani et al. 2008, 2015; Fontana et al. 
2009; Rochon et al. 2008; Rockey et al. 2010]. In brief, it is comprised of several clinical 
centers (currently 6 in number) that identify and enroll subjects with acute liver injury due to 
drugs, herbals or dietary supplements. A formal method for assessing causality, based upon 
expert opinion of experienced hepatologists, is an important part of the US DILIN because 
of the difficulty of identifying the cause of liver injury and the need to exclude non-drug 
causes. Subjects may be enrolled at any time within 6 months of the onset of acute liver 
injury. Demographic and clinical data are collected, and samples of blood and urine are 
collected and stored in sample repositories. The Duke Clinical Research Institute serves as 
the Central Data Repository and Coordinating Center for the Network.
Blood collection and PBMC isolation for initial feasibility experiments
Whole blood was collected into heparinized tubes at the Pfizer Occupational Health Office 
from human donors with a history of allergic drug reactions or donors with no history of 
allergic drug reaction. Blood samples were obtained after donors had provided informed 
consent and signed written informed consent forms. Donor recruitment and blood collection 
procedures followed protocols approved by the Pfizer Institutional Review Board.
PBMC were isolated using Lymphoprep™ (STEMCELL Technologies, Vancouver, British 
Columbia) according to the manufacturer’s instructions. Following cell isolations, counts per 
milliliter of whole blood were determined by an Advia™ 120 Hematology System (Siemens 
Healthcare Diagnostics Inc., Deerfield, IL) and converted into total PBMC per milliliter of 
whole blood. Twenty million cells were cryogenically frozen in 1 ml freezing media (10% 
DMSO [Sigma, St. Louis, MO] + 90% filtered heat-inactivated fetal bovine serum [FBS; 
Invitrogen, Grand Island, NY]) and stored in a liquid nitrogen tank until used for analysis in 
the mLTT.
Modified Lymphocyte Transformation Test
In brief, 5 × 105 PBMC in 200 μl medium (RPMI [Invitrogen] supplemented with 2–4% 
human AB serum, 2 mM L-glutamine [Invitrogen], 25 ng/ml human transferrin [Sigma], and 
50 μg/ml gentamicin [Sigma]) were added to individual wells of a 96-well U-bottomed cell 
culture plate (Corning Inc., Corning, NY). Cells were treated with either 5 μg/ml anti-human 
CD3 (Clone HIT3a, BD Biosciences, San Jose, CA) as a positive control or with the relevant 
drug (concentration[s] dependent on threshold for cytotoxic effects; data not shown). In 
some cases, cells were also treated with an irrelevant drug that was not associated with 
reported allergic response (metformin) to determine specificity of the mLTT. Drugs 
(purchased from Sigma) and the ranges of concentrations of drugs tested are indicated in 
Table 2. For each donor, untreated (non-stimulated) PBMCs served as the negative control. 
Following addition of the appropriate treatment/compounds, cells were cultured in a 5% 
CO2 incubator at 37°C for 3 days. At the end of the incubation period, plates were 
centrifuged (800 × g) for 10 min and the supernatants collected and stored at −20°C until 
cytokine and granzyme B analyses were carried out.
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Cytokine measurements
Multiplex cytokine assay kits (Millipore Corp., Billerica, MA and Meso Scale Discovery 
[MSD], Rockville, MD) were used for the cytokine analysis. Interleukin (IL)-2, IL-5, IL-13 
and interferon (IFN)-γ were selected for analysis based on previous work that demonstrated 
the sensitivity of these cytokines in drug allergy responses (Lochmatter et al. 2009). The 
multiplex bead assay (Millipore) uses beads internally tagged with fluorescent dyes and 
coated with specific cytokine antibodies to capture cytokines of interest. The internal 
fluorescent dyes and surface coating of various antibodies allows detection of multiple 
cytokines in a single sample. Once the beads captured the cytokines, biotinylated detection 
antibody was added for signal amplification, followed by incubation with Streptavidin-PE 
(phycoerythrin) conjugate as a fluorescent reporter molecule. After the incubation, each 
bead passes through two lasers: the first one excites the internal fluorescent dyes to identify 
each analyte, and the second laser excites the reporter molecule to quantify signals from 
each analyte. All measures were performed in a Bio-Rad® Bio-Plex System using Bio-Plex 
Manager™ software (Bio-Rad, Hercules, CA) to analyze the data outputs. The level of 
sensitivity of the kit was 3.2 pg cytokine/ml.
The MSD cytokine assay plates are pre-coated with capture antibodies spotted at the bottom 
of the wells. Calibrators or samples are incubated in the multi-spot plate and each cytokine 
binds its corresponding capture antibody. Cytokine levels are then measured using a 
cytokine specific detection antibody with MSD SULFO-TAGTM. All measures were 
performed in a in a MSD 6000 system using Discovery Workbench TM (MSD) software to 
analyze the data outputs. The level of sensitivity of the kit was 2.4 pg cytokine/ml.
Both multiplex assays were performed according to the manufacturer protocols. Data are 
presented for each cytokine in pg/ml or as stimulation index (SI) determined by dividing 
cytokine production of the stimulated PBMC by that of the non-stimulated PBMC.
Granzyme B measurements
A commercially available ELISA kit was used to quantify granzyme B (Cell Sciences, 
Canton, MA). The assay was performed as per the manufacturer protocols. Data are 
presented in pg/ml or as a SI determined by dividing granzyme B production of the 
stimulated PBMC by granzyme B production of the non-stimulated PBMC. The level of 
sensitivity of the kit was 20 pg granzyme B/ml.
DILIN Sample Testing
PBMC (isolated as described above) obtained from DILIN subjects (Chalasani et al. 2008, 
2015; Fontana et al. 2009) were tested in the mLTT and cytokine (IL-2, IL-5, IL-13, IFNγ) 
and granzyme B concentrations were determined as described above for the respective 
endpoints. To increase the likelihood of success in identifying a positive response in the 
mLTT, subjects that experienced DILI reactions with drugs often associated with drug 
allergy and/or subjects that displayed clinical features such as rash, fever, and/or 
eosinophilia were prioritized for testing (Table 3); this resulted in a total of 33 samples from 
24 DILIN subjects being tested.
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Results
mLTT Assay Performance (Cytokines and Granzyme B)
Due to the lack of availability of positive control samples for DILI associated with an 
adaptive response, PBMC collected from 10 healthy donors that had previously experienced 
an allergic reaction (manifested as a skin reaction) to a specified drug(s) (considered positive 
controls) were used to evaluate the performance of the mLTT. Samples collected from 11 
healthy donors with no reported allergic reactions to drugs (considered negative controls) 
were also tested in the assay. Responses in the mLTT for positive and negative control donor 
PBMC samples are reported in Table 4. A positive mLTT response was defined as an SI ≥ 2 
for ≥ 3 of five analytes (e.g., IL-2, IL-5, IL-13, IFNγ, granzyme B) at one or more drug 
concentrations tested.
Samples from most positive control donors had a positive mLTT response when tested with 
their relevant respective drugs (that is, the drug that was associated with a previous allergic 
reaction). However, the positive mLTT response was not consistently reproducible in 
subsequent experiments using PBMC samples from one positive control donor (Donor 
D110). Repeat experiments were not performed with samples from the other positive control 
donors due to inadequate numbers of PBMC. Negative mLTT responses were observed for 
samples from positive control donors tested with the irrelevant drug, metformin. Positive 
mLTT responses were observed for samples from some negative control donors. 
Specifically, PBMC samples from 3 of the 10 negative control donors responded to one or 
more of the drugs tested.
DILIN sample testing in the mLTT
A total of 33 PBMC samples from 24 DILIN subjects were tested in the mLTT, which 
included baseline (defined as the first PBMC sample collected following the DILI reaction) 
and 6-mo follow-up samples from nine DILIN subjects (Table 3). Samples from most 
subjects had negative mLTT responses based on levels of cytokines and granzyme B (data 
not shown). For those few samples that did produce a positive mLTT response (six samples 
from five subjects; indicated in Table 3 with shading and in Table 5), the positive response 
was not reproducible in repeat experiments, with the exception of one sample from a subject 
with INH-related DILI (Subject ID 87). For this subject, a positive mLTT response was 
observed for the 6-month follow-up sample at the highest INH concentration tested in two 
independent experiments; the baseline sample for this subject (Subject ID 8) did not produce 
a positive response in the mLTT. A baseline sample from a second subject (Subject ID 23) 
was negative in the mLTT when PBMC were tested with SMX. However, in a subsequent 
experiment, a robust positive cytokine and granzyme B response was observed when the 
PBMC sample from this subject was tested in the mLTT with INH and INA (but not SMX or 
Trim). Unfortunately, no additional PBMC samples were available from this subject to 
confirm the positive mLTT result with INH or INA.
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Discussion
DILI is a diagnosis of exclusion and it is both under-recognized and under-reported 
(Bonkovsky et al. 2012). Even when the diagnosis is made, it is often difficult to ascertain 
which of several possible causative drugs or herbals/dietary supplements are the cause of the 
liver injury. This is a growing problem in the current era of polypharmacy for most patients, 
especially those in older age groups who are more susceptible to DILI (Bonkovsky et al. 
2012; DeLemos et al. 2016) and in whom chronic and ongoing DILI are more likely 
(Fontana et al. 2015). Thus, there is growing need for a simple and reliable biomarker, both 
to identify those with DILI and to predict likely clinical outcomes. In the latter regard, a 
combination of levels of four cytokines and albumin in the serum was recently found to have 
high accuracy for predicting prognosis of acute DILI (Steuerwald et al. 2013).
The overall objective of this study was to optimize the mLTT in order to determine if this in 
vitro test could be used to identify DILI reactions associated with an adaptive immune 
response. In reports from other investigators, the traditional LTT (used as a diagnostic tool 
for allergic drug reactions) has been shown to result in positive responses in subjects with 
DILI and, in Japan, the assay is used rather widely to support the diagnosis of DILI and to 
implicate the putative responsible drugs (Watanabe and Shibuya 2004).
In contrast, however, data from the current study suggest that the mLTT, using cytokines and 
granzyme B production to determine lymphocyte sensitization to a specific drug, is not 
useful or reliable for diagnosing DILI associated with an adaptive immune response under 
the conditions tested. Although a positive control sample from a subject with known DILI 
associated with an adaptive immune response was not available to assess the performance of 
the mLTT, the cytokine and granzyme B data generated with the available drug allergy 
positive control donors were not reproducible, nor were robust responses observed.
Even though robust, reproducible responses were not observed in the mLTT with samples 
from positive control donors with a history of drug allergies (manifested as skin reactions), 
samples from selected DILIN subjects were tested in the assay. In order to allow for the 
greatest probability of success in identifying subjects with DILI reactions associated with an 
adaptive immune response, samples from DILIN subjects that had clinical features 
associated with drug allergy (e.g., fever, rash, and/or eosinophilia) (Castell and Castell 2006; 
Bonkovsky et al. 2012) and/or whose liver injury was associated with a drug known to cause 
drug allergy, were selected for testing in the mLTT. Similar to what was observed for 
samples from the drug allergy positive control donors, the majority of samples tested in the 
mLTT from the DILIN subjects produced non-robust cytokine and granzyme B responses. 
Samples from only one DILIN subject showed reproducible responses in cytokines and 
granzyme B in the mLTT. In this particular case (Subject ID 87) where the responsible drug 
was INH, the positive mLTT response was only observed in the 6-month follow-up sample, 
and not the baseline sample, and the response was observed following incubation of PBMC 
with both INH and its metabolite INA. Positive LTT responses have been previously 
reported for cases of INH-induced hepatotoxicity (Warrington et al. 1978, 1982), and a role 
for the immune system in contributing to INH-induced liver injury has been described 
(Metushi et al. 2011). It is worth noting that for the 3 DILIN subjects with INH associated 
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liver injury, samples from all three subjects had a positive mLTT response in at least one 
experiment. These results are consistent with the 95% positive LTT response rate observed 
in INH-induced hepatitis cases reported by Warrington et al. (1978).
Because in prior studies positive LTT responses have been observed in subjects with what 
appeared to be DILI associated with an adaptive immune response, the lack of consistently 
and/or strongly positive results in the mLTT described herein was unexpected. Several 
factors may have contributed to the lack of positive responses in the DILIN subject samples 
tested in the mLTT. One such factor is the unavoidable delay that occurred in isolating the 
PBMCs from the whole blood samples that were collected from the DILIN subjects. For this 
study, whole blood samples were collected at DILIN sites across the United States and then 
shipped by overnight air to a central processing center where PBMCs were isolated and 
frozen. The delay in PBMC isolation from whole blood samples may have significantly 
decreased antigen-specific T-cell responses. In addition, timing of the collection of PBMCs 
relative to the onset of clinical symptoms of an allergic reaction has also been shown to be 
important in detecting responses in the LTT (Kano et al. 2007). This may be particularly 
important in the case of DILI, where drug-specific T-cells may not be in circulation (at least 
in large numbers) at the time of blood collection and PBMC isolation, especially when these 
were long after the acute reaction. The concentration of drug tested has also been shown to 
be important; dose-dependent responses are not always observed in the LTT, which is why it 
is recommended to test a range of drug concentrations in the assay.
For this study, due to the limited numbers of PBMC available per subject, it was not possible 
to test a wide range of concentrations, perhaps, reducing the likelihood of detecting a 
positive response in the assay. Then, too, it may not have been the parent molecule that 
initiated the DILI response; in some (or all subjects), testing drug metabolites and/or drug-
protein conjugates may be necessary to elicit a response in the ex vivo LTT. However, with 
the exception of INA (the metabolite of INH), only the parent molecules were tested in these 
studies due to the limited number of PBMC available for each DILIN subject. Finally, 
another possibility that cannot be excluded for why positive responses in the mLTT were not 
observed for most DILIN subjects is that the DILI reaction in these particular subjects may 
not have been driven by an adaptive immune mechanism.
Conclusions
Samples from all of the DILIN subjects were negative or not reproducible in the mLTT, with 
the exception of one subject with INH-associated liver injury. Therefore, it could be 
concluded that lack of responses from PBMC collected from cases with phenotypes of 
immuno-allergic DILI could be due to one or a combination of the following reasons: (1) 
DILI reactions were not mediated by drug-specific T-cells, (2) the mLTT as used in these 
studies was not sensitive enough, (3) responsiveness of drug-specific T-cells decreased with 
the 24-hr period between shipment and PBMC preparation, and/or (4) drug metabolites/
drug-protein conjugates were not tested for most samples. Given the limitations of the assay, 
we concluded the mLTT, as performed here, is not a robust test for diagnosing DILI 
associated with an adaptive response caused by all drugs. However, the mLTT may be useful 
for diagnosing or confirming DILI ascribed to INH.
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Table 1
Positive Lymphocyte Transformation Test Responses in Patients with Drug-induced Liver Injurya
Reference Cases Percent Positive Responses Endpoint Comments
Mizoguchi et al. 1975 70 12.8% [3H]-uridine uptake
Systemic features included skin eruption 
(60%), fever (69%), itching (73%), and 
eosinophilia (50%)
Warrington et al. 1978 20 95% [3H]-thymidine uptake All patients had INH-associated liver injury
Yoshimura et al. 1994 113 41.3% MTT assay Systemic features included itching (53%), eruption (35%), and fever (32%)
Maria and Victorino 1997 95 26% (w/o PG inhibitor)56% (w/PG inhibitor) [3H]-thymidine uptake
Systemic features included fever (39%), 
rash (29%) and eosinophilia (53%)
Murata et al. 2003 17 52.9% IFNγ production by CD8+ 
cells
a
These studies did not indicate the amount of time between blood collection and peripheral blood mononuclear cells (PBMC) processing. It is 
assumed that fresh PBMC were used for these assays since the freezing of PBMC prior to use in the lymphocyte transformation test was not 
described.
INH-isoniazid; PG-prostaglandin; MTT-3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; w/o-without.
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Table 2
Drugs Tested in the Modified Lymphocyte Transformation Test
Name Abbreviation Concentration(s) (μg/ml)a
Allopurinol ALL 0.1, 1, 10, 100
Amoxicillin AMX 50, 100, 200, 500
Carbamazepine CBZ 10, 50
Clavulanic Acid CA 10, 50
Isoniazid INH 10, 100, 200
Isonicotinic Acid INA 10, 100, 200
Levofloxacin Not used 50, 100
Metformin MET 100
Minocycline Not used 0.01, 0.1, 1, 10, 50
Moxifloxacin Not used 100
Nitrofurantoin Not used 50, 100
Phenytoin PHE 10, 50, 100
Sulfamethoxazole SMX 50, 100, 200
Trimethoprim TP 10, 25, 50
Valproic Acid VA 1, 10, 50, 100
aNot all concentrations tested in samples from all donors.
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Table 4
Sensitivity and Specificity of the Modified Lymphocyte Transformation Testa
Donor Identification Drug(s) Tested mLTT Responseb
Positive Control Donors D110 SMX, MET +/− (SMX)
PID11 SMX + (SMX)
PID31 AMX + (AMX)
PID492 AMX + (AMX)
D33 AMX, MET −
PAT32 AMX, PHE, SMX, MET + (AMX, PHE, SMX)
PAT47 CBZ, MET + (CBZ)
PAT535 SMX, MET + (SMX)
PAT553 CBZ, PHE, MET + (CBZ, PHE)
PAT577 SMX, Trim, MET + (SMX, Trim)
Negative Control Donors D138 AMX, SMX −
D206 AMX, SMX −
D6 MET, AMX, CA, ALL, SMX, Trim + (MET, AMX)
D10 MET, AMX, CA, ALL, SMX, Trim −
D229 MET, AMX, CA, ALL, SMX, Trim + (CA)
HD1 AMX, SMX, PHE, MET −
HD2 SMX, Trim, MET + (SMX, Trim)
HD3 SMX, MET −
HD4 CBZ, PHE, MET −
HD5 CBZ, MET −
a
PBMC from each subject were incubated with drug for 72 hr.
b
Positive response defined as a stimulation index ≥ 2 for ≥ 3 of five analytes (IL-2, IL-5, IL-13, IFNγ, granzyme B) at one or more drug 
concentrations tested.
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D
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D
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D
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D
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D
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X
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<
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.2
<
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<
 2
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<
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<
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.4
<
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<
 3
.2
<
 3
.2
<
 3
.2
<
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.2
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.4
N
D
N
D
N
D
N
D
N
D
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<
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.4
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4
<
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.4
<
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.4
<
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0
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3.
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+
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.6
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.5
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.2
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6
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D
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D
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D
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1
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9
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54
0.
6
M
ET
 (1
00
 μg
/m
l)
6.
5
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<
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0
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8
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9
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6
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bje
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38
)
M
ed
ia
<
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.4
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<
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.4
3.
7
<
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0
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.6
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.6
<
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.4
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0
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3
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.3
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3
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0
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.6
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<
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<
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0
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D
N
D
N
D
N
D
N
D
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.3
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0
+
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8
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6
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8.
1
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7
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0
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3
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8
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0
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6
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.6
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4
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0
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5
3.
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+
19
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.3
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.2
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1
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0
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7.
8
>
10
00
+
N
D
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D
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D
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D
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.3
<
 2
.4
4.
4
<
 2
.4
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D
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0
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+
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9
64
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<
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.4
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.4
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.9
N
D
N
D
N
D
N
D
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D
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0.
2
<
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.4
3.
0
<
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.4
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8.
8
N
D
N
D
N
D
N
D
N
D
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 (1
00
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/m
l)
N
D
N
D
N
D
N
D
N
D
58
8.
7
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.7
<
 2
.4
4.
6
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6.
9
a S
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ng
 in
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ca
te
s a
n 
SI
 ≥
 2
.
b P
os
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v
e 
re
sp
on
se
 d
ef
in
ed
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s ≥
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 st
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ul
at
io
n 
in
de
x
 (S
I) 
for
 ≥ 
3 o
f f
iv
e 
an
al
yt
es
 (I
L-
2, 
IL
-5,
 IL
-13
, IF
Nγ
,
 
gr
an
zy
m
e 
B)
.
c V
A
 te
ste
d 
at
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on
ce
nt
ra
tio
ns
 o
f 1
0,
 5
0,
 an
d 
10
0 
μg
/m
l i
n 
Ex
pe
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en
t 1
 an
d 
1,
 1
0,
 an
d 
10
0 
μg
/m
l i
n 
Ex
pe
rim
en
t 2
.
d R
es
po
ns
es
 fo
r S
ub
jec
t 2
3 i
n E
xp
eri
me
nt 
1 w
ere
 fr
om
 a 
6-d
 in
cu
ba
tio
n;
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X
 =
 su
lfa
m
et
ho
xa
zo
le
; T
rim
 =
 tr
im
et
ho
pr
im
; I
N
A
 =
 is
on
ic
ot
in
ic
 a
ci
d;
 IN
H
 =
 is
on
ia
zi
d;
 M
ET
 =
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et
fo
rm
in
; V
A
 =
 v
al
pr
oi
c 
ac
id
; N
D
 =
 n
ot
 d
on
e.
J Immunotoxicol. Author manuscript; available in PMC 2017 December 01.
